Dihydroartemisinin (DHA) has attracted increasing attention as an anticancer agent. However,using DHA to treat cancer usually depends on the synergistic effects of exogenous components,a nd the loss of DHA during delivery reduces its effectiveness in cancer therapy. Reported herein is ap rogrammed release nanoplatform of DHA to synergistically treat cancer with aF e-TCPP [(4,4,4,4-(porphine-5,10,15,20-tetrayl) tetrakis(benzoic acid)] NMOF (nanoscale MOF) having aC aCO 3 mineralizedc oating, whichp revents DHA leakage during transport in the bloodstream. When the nanoplatform arrives at the tumor site,t he weakly acidic microenvironment and high concentration of glutathione (GSH) trigger DHA release and TCPP activation, enabling the synergistic Fe 2+ -DHA-mediated chemodynamic therapy, Ca 2+ -DHA-mediated oncosis therapy, and TCPP-mediated photodynamic therapy.In vivo experiments demonstrated that the nanoplatform showed enhanced anticancer efficiency and negligible toxicity.